Home » Business News » 2012 » November » November 26, 2012

Galapagos discovers novel class of antibiotics

November 26, 2012 - Mechelen, Belgium

First candidate antibiotic is effectiveagainst all tested MRSA strains

· May offer treatment against multiple drug-resistantinfections

· Proprietary to Galapagos, based on novel target DNApol IIIalpha (DnaE)

· Clinical development of first antibiotic initiated

Galapagos NV (Euronext: GLPG) announcedtoday that it has discovered an entirely new class of antibiotics. TheCompanyhas selected a candidate drug that shows strong activity against all testeddrugresistant Staphylococcus aureus, including hospital and community acquiredMRSAstrains.

Bacterial infections that have become resistant to all existing antibioticsposea pressing healthcare problem because treatment options for patients becomeverylimited. MRSA is the best known example: a potentially life-threateninginfection that occurs most frequently among patients in hospitals. ThenovelGalapagos candidate antibiotic shows strong activity against all testeddrugresistant bacteria.

This newly discovered antibiotic works by inhibiting the target DNA pol IIIalpha, an enzyme present in all bacteria and essential for their growth;thistarget is absent in humans. The novel mode of action - inhibition of DNApolIII alpha - may be used to explore a variety of novel antibiotics,targetingbacteria for which resistance to current antibiotics has emerged.

Using this novel target, Galapagos has selected a first candidateantibiotic,CAM-1, to enter drug development. CAM-1 was tested against more than250different bacterial strains and effectively killed 100% of all drugresistantStaph. aureus, including MRSA. CAM-1 shows better efficacy thanstandardantibiotics, as shown by in vivo bacterial infection models. Galapagosaims toenter the clinic in the first quarter 2014, with a Proof of Conceptstudythereafter. This novel antibiotic program, including all compoundstargetingMRSA, is fully proprietary to Galapagos.

"Selection of a candidate antibiotic in our MRSA development programis animportant step toward realizing the full potential of our unique anti-bacterialprogram," said Dr Piet Wigerinck, Chief Scientific Officer of Galapagos."Ourantibiotics have a novel mode of action which brings all tested MRSAstrains toa complete halt. Combined with a diagnostic test, these compounds couldbring areal solution to MRSA infections."

About MRSA

Drug resistant infections including MRSA (Methicillin ResistantStaphylococcusaureus) occur most frequently among patients in healthcare settings.Globally,MRSA treatment with antibiotics generates an estimated $4 billion inannualrevenues[1]. Development of new treatments within existingclasses ofantibiotics is complicated by the short timeframe in which resistanceto theantibiotic emerges. Regulators encourage development of narrowspectrumantibiotics in order to address this dilemma. Current advancements inrapiddiagnostic tests to identify the bacterial strain responsible for theinfectionprovide an opportunity for the development of targeted, narrowspectrumantibiotics.

About Galapagos

Galapagos (Euronext: GLPG; OTC: GLPYY) is a mid-size clinicalstagebiotechnology company specialized in the discovery and development ofsmallmolecule and antibody therapies with novel modes-of-action. Thecompany isprogressing its JAK1 inhibitor GLPG0634, as well as one of the largestpipelinesin biotech, with four programs in development and over 30 discoveryprograms.The Galapagos Group has over 800 employees and operates facilitiesin sixcountries, with global headquarters in Mechelen, Belgium. Moreinfo

This release may contain forward-looking statements, including,withoutlimitation, statements containing the words "believes,""anticipates,""expects," "intends," "plans," "seeks," "estimates," "may," "will,""could,""stands to," and "continues," as well as similar expressions. Suchforward-looking statements may involve known and unknown risks, uncertainties andotherfactors which might cause the actual results, financial condition,performanceor achievements of Galapagos, or industry results, to be materiallydifferentfrom any historic or future results, financial conditions,performance orachievements expressed or implied by such forward-looking statements.Giventhese uncertainties, the reader is advised not to place any unduereliance onsuch forward-looking statements. These forward-looking statements speakonly asof the date of publication of this document. Galapagos expresslydisclaims anyobligation to update any such forward-looking statements in thisdocument toreflect any change in its expectations with regard thereto or anychange inevents, conditions or circumstances on which any such statement is based,unlessrequired by law or regulation.


[1]"MRSA Drug Futures,"Epsicom, Sept. 2010

This announcement is distributed by Thomson Reuters on behalf ofThomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Galapagos NV via Thomson Reuters ONE



Galapagos NV
Dr Piet Wigerink
Chief Scientific Officer
Tel. +32 477 627103

Elizabeth Goodwin
Director Investor Relations
Tel: +31 6 2291 6240
Email Contact


Comment on this story